These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

139 related articles for article (PubMed ID: 29790193)

  • 1. Myasthenic ophthalmoparesis: Time To resolution after initiating immune therapies.
    Europa TA; Nel M; Heckmann JM
    Muscle Nerve; 2018 Oct; 58(4):542-549. PubMed ID: 29790193
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Therapy in myasthenia gravis and Lambert-Eaton myasthenic syndrome.
    Newsom-Davis J
    Semin Neurol; 2003 Jun; 23(2):191-8. PubMed ID: 12894384
    [TBL] [Abstract][Full Text] [Related]  

  • 3. IVIG Versus PLEX in the Treatment of Worsening Myasthenia Gravis: What is the Evidence?: A Critically Appraised Topic.
    Dhawan PS; Goodman BP; Harper CM; Bosch PE; Hoffman-Snyder CR; Wellik KE; Wingerchuk DM; Demaerschalk BM
    Neurologist; 2015 May; 19(5):145-8. PubMed ID: 25970838
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The characteristics of juvenile myasthenia gravis among South Africans.
    Heckmann JM; Hansen P; Van Toorn R; Lubbe E; Janse van Rensburg E; Wilmshurst JM
    S Afr Med J; 2012 May; 102(6):532-6. PubMed ID: 22668957
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Baseline Decrement in Patients with Mild Myasthenia Gravis Predicts Immunomodulation Treatment.
    Abraham A; Lovblom LE; Bril V
    Can J Neurol Sci; 2019 Nov; 46(6):762-766. PubMed ID: 31322098
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Therapeutic plasma exchange in a patient of myasthenic crisis, refractory to intravenous immunoglobulin and immunosuppressive therapy.
    Prakash S; Hans R; Sharma RR; Lal V; Marwaha N
    Neurol India; 2017; 65(6):1409-1412. PubMed ID: 29133726
    [No Abstract]   [Full Text] [Related]  

  • 7. Myasthenia gravis: emerging new therapy options.
    Sieb JP
    Curr Opin Pharmacol; 2005 Jun; 5(3):303-7. PubMed ID: 15907918
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cross-sectional analysis of the Myasthenia Gravis Patient Registry: Disability and treatment.
    Cutter G; Xin H; Aban I; Burns TM; Allman PH; Farzaneh-Far R; Duda PW; Kaminski HJ
    Muscle Nerve; 2019 Dec; 60(6):707-715. PubMed ID: 31487038
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A review of the histopathological findings in myasthenia gravis: Clues to the pathogenesis of treatment-resistance in extraocular muscles.
    Europa TA; Nel M; Heckmann JM
    Neuromuscul Disord; 2019 May; 29(5):381-387. PubMed ID: 31029532
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Myasthenic crisis after a renal transplant successfully treated with intravenous immunoglobulin.
    Hwang IH; Lee KN; Kim IY; Lee DW; Lee SB; Kim DS; Song SH; Seong EY; Kwak IS
    Exp Clin Transplant; 2014 Dec; 12(6):555-8. PubMed ID: 24568644
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Validation of the ice pack test in ophthalmoparesis due to myasthenia gravis].
    Ramirez-Antunez ÁG; García-Ramos G; Estañol-Vidal B; Juárez-Flores A
    Rev Neurol; 2013 Nov; 57(9):385-95. PubMed ID: 24150950
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Allogeneic hematopoietic cell transplantation for refractory myasthenia gravis.
    Strober J; Cowan MJ; Horn BN
    Arch Neurol; 2009 May; 66(5):659-61. PubMed ID: 19433668
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Plasma exchange combined with cytotoxic drugs and lymphocytapheresis for myasthenia gravis.
    Valbonesi M; Garelli S; Zerbi D; Forlani G; Cornelio F; Pelucchetti D
    Vox Sang; 1982; 43(3):142-6. PubMed ID: 7147857
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Myasthenia gravis: how to treat?
    Tireli H; Karlikaya G; Tutkavul K; Akpinar A; Okay T
    Acta Myol; 2004 Dec; 23(3):140-5. PubMed ID: 15938570
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Periodic therapeutic plasma exchange in patients with moderate to severe chronic myasthenia gravis non-responsive to immunosuppressive agents: an eight year follow-up.
    Triantafyllou NI; Grapsa EI; Kararizou E; Psimenou E; Lagguranis A; Dimopoulos A
    Ther Apher Dial; 2009 Jun; 13(3):174-8. PubMed ID: 19527462
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A single-blinded trial of methotrexate versus azathioprine as steroid-sparing agents in generalized myasthenia gravis.
    Heckmann JM; Rawoot A; Bateman K; Renison R; Badri M
    BMC Neurol; 2011 Aug; 11():97. PubMed ID: 21819556
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Myasthenia gravis].
    Fleury MC; Tranchant C
    Rev Prat; 2008 Dec; 58(20):2217-24. PubMed ID: 19209651
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Plasma exchange versus intravenous immunoglobulin treatment in myasthenic crisis.
    Qureshi AI; Choudhry MA; Akbar MS; Mohammad Y; Chua HC; Yahia AM; Ulatowski JA; Krendel DA; Leshner RT
    Neurology; 1999 Feb; 52(3):629-32. PubMed ID: 10025801
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Randomized trial of azathioprine or prednisone for initial immunosuppressive treatment of myasthenia gravis.
    Bromberg MB; Wald JJ; Forshew DA; Feldman EL; Albers JW
    J Neurol Sci; 1997 Sep; 150(1):59-62. PubMed ID: 9260858
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Myasthenic crisis following iodinated contrast material (iohexol) aspiration: a case report.
    Bopeththa BVKM; Hewavithana PB; Hewapathirana HLI; Ralapanawa U
    J Med Case Rep; 2019 May; 13(1):166. PubMed ID: 31146780
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.